Stockreport

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Barinthus Biotherapeutics plc - American Depositary Shares  (BRNS) 
PDF VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tole [Read more]